Paris, May 17, 2021: Sanofi, the French pharmaceutical giant is developing a Corona virus vaccine in partnership with Britain’s GSK group, further raising hopes another player can join in the fight against the pandemic.
So far France was the only member of the UN security council who did not have success in developing and producing its own COVID-19 vaccine, with the UK, US, China and Russia all having developed and distributed theirs.
According to public statements, the company said on Monday that after the Phase 2 study result they can positively say the vaccine is capable of triggering a strong immune response. The company also said the results of these tests will now enable them to move to final and late stage global and pivotal phase 3 trials in the coming weeks. They said the test doses of the vaccine were able to achieve strong rates of neutralizing antibodies in people who have recovered from COVID-19 in all adult age groups amongst the 722 volunteers who were tested.
The research by Sanofi was initially dealt a blow last year when a study in late 2020 showed it provided only a low immune response in older adults. If the Phase 3 trials and testing go according to plan, the vaccine will be ready by the end of 2021.
According to Thomas Triomphe, the executive Vice President and global head of Sanofi Pasteur group, “Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis. As we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increases.
The joint research teams of GSK and Sanofi are currently combining an antigen developed by Sanofi, which is capable of stimulating the growth of virus killing antibodies along with adjuvant technology from GSK that will bolster the initial immune response triggered by the vaccine
Stay tuned to BaaghiTV for latest news and Updates!
